Sedia Biosciences Announces ISO 13485 Certification for Production of HIV In Vitro Diagnostics Tests

Sedia Biosciences Corporation today announced that it has received ISO 13485:2016 Certification of its Beaverton, OR facilities for the production and distribution of two of its key Products. ISO 13485 is an internationally recognized quality standard for medical devices and Certification was provided by TÜV SÜD Product Service GmbH, of Munich Germany, an International Organization for Standardization (ISO) Certification Body.

By |February 3, 2022|

Sedia Biosciences Announces Expansion and Move to New Research and Manufacturing Facility

Sedia Biosciences Corporation, formerly of Portland Oregon, today announced the relocation to and opening of their new assay development and manufacturing facility in Beaverton, Oregon. The 27,000 square foot facility provides for both current growth as well as additional near-term expansion and enables immediate scale-up of manufacturing capacity as well as research capabilities.

By |July 30, 2020|

Sedia Biosciences and Floragenex Announce Completion of Merger

Sedia Biosciences Corporation (Portland, OR) and Floragenex Inc. (Eugene, OR) today announced the merger of their companies. Sedia will continue the business of Floragenex as a wholly-owned subsidiary with current Floragenex Chief Executive Officer, Dr. Rick Nipper continuing oversight of the new subsidiary.

By |October 19, 2016|

Sedia Biosciences Awarded Additional $1.8 M NIH Grant for Novel Rapid HIV Test for Recent Infections

Sedia Biosciences Corporation has received notification from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH) of the award of a $1.8 Million Phase II Small Business Innovation Research (SBIR) Grant to accelerate development of Sedia’s Asanté ® HIV-1 Rapid Recency™ Assay.

By |August 30, 2016|


Want to know more or have any questions? Send us a message!

This field is for validation purposes and should be left unchanged.
Go to Top